HCV Treatment
PSI-7977 with Standard Therapy Produces 91% Sustained Response
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 09 September 2011 00:00
- Written by Pharmasset
The experimental hepatitis C virus (HCV) nucleotide analog polymerase inhibitor PSI-7977, used in combination with pegylated interferon and ribavirin, demonstrated a 12-week sustained virological response rate of 91% for previously untreated genotype 1 chronic hepatitis C patients in the ongoing PROTON trial.
HALT-C Finds High Rate of Liver-Related Death and Transplants among Interferon Non-Responders
- Details
- Category: HCV Treatment
- Published on Friday, 09 September 2011 00:00
- Written by Liz Highleyman
Chronic hepatitis C patients in the HALT-C study who did not achieve sustained response to standard combination therapy or long-term pegylated interferon maintenance therapy had a high rate of liver transplantation and liver-related death, researchers reported in the August 2011 issue of Hepatology.
What Factors Influence Adherence to Treatment for Hepatitis C?
- Details
- Category: HCV Treatment
- Published on Thursday, 01 September 2011 00:00
- Written by James Learned
Efficacy, or likelihood of achieving sustained virological response, was the most important factor influencing adherence among people considering treatment for chronic hepatitis C, according to a recent survey. Other factors affecting adherence included depression, flu-like symptoms days, lost work days, hair loss, and type of interferon injection equipment.
TMC435 for Hepatitis C Phase 3 Studies Fully Enrolled, Company Says
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 September 2011 00:00
- Written by Medivir
Medivir announced last week that Phase 3 clinical trials of its investigational hepatitis C virus (HCV) protease inhibitor, TMC435 (initially developed by Tibotec/Janssen), are have completed enrollment and participants have begun receiving randomized treatment.
FDA Approves Pegasys plus Ribavirin for Children with Chronic Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 August 2011 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) has approved pegyalted interferon alfa-2a (brand name Pegasys) plus ribavirin (brand name Copegus) for previously untreated children and adolescents age 5-17 with chronic hepatitis C virus (HCV) infection. 
Web Design and Development by